加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.7602
−US$0.0048 · -0.63%
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
常规交易时段
US$0.7601
−US$0.0049 · -0.64%
盘中时间采用ET。市场数据可能有所延迟。
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
日内区间
当前US$0.7601
52周区间
当前US$0.7601
盘中时间采用ET。市场数据可能有所延迟。
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
日内区间
当前US$0.7601
52周区间
当前US$0.7601
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 154.6万 USD | — | 100万 USD | 500万 USD | 1500万 USD |
| 销货成本 | 11.4万 USD | — | — | — | — |
| 毛利 | 143.2万 USD | — | 100万 USD | 500万 USD | 1500万 USD |
| 研究与开发 | 1810.8万 USD | 1435.7万 USD | 3105.2万 USD | 3982.9万 USD | 3867.1万 USD |
| 销售、一般及管理费用 | 1727.4万 USD | 2774.5万 USD | 3104.6万 USD | 2481.3万 USD | 1940.2万 USD |
| 营业费用 | 6391.7万 USD | 4210.2万 USD | 6209.8万 USD | 6464.2万 USD | 5807.3万 USD |
| 利息收入 | 292万 USD | 416.4万 USD | 396.7万 USD | 125.4万 USD | 22万 USD |
| 利息支出 | 383.8万 USD | −358.1万 USD | 255.4万 USD | — | — |
| 折旧和摊销 | 11.4万 USD | 10.5万 USD | 9.2万 USD | 8.9万 USD | 36.2万 USD |
| 营业利润 | −6248.5万 USD | −4210.2万 USD | −6109.8万 USD | −5964.2万 USD | −4307.3万 USD |
| 净利润 | −6305.8万 USD | −4151.9万 USD | −5968.5万 USD | −5838.8万 USD | −4285.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
